These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36794567)

  • 1. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.
    Ye C; Lin S; Hong J; Liu F; Guo G; Chen S; Zhou Z; Lin W; Li J; Ye Y
    Eur J Immunol; 2023 May; 53(5):e2250054. PubMed ID: 36794567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induction of specific CD8(+) T cells against hepatocellular carcinoma-associated neoantigens].
    Wang YM; Zhao BH; Chen K; Li ZJ; Qu CF
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):429-434. PubMed ID: 31216828
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma.
    Dong HL; Li ZS; Ye J; Qu P; Huang YY; Wu W; Lu SY; Chen GS; Sui YF
    Cancer Biol Ther; 2004 Sep; 3(9):891-8. PubMed ID: 15326372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma.
    Yang H; Sun L; Guan A; Yin H; Liu M; Mao X; Xu H; Zhao H; Lu X; Sang X; Zhong S; Chen Q; Mao Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):667-677. PubMed ID: 32876735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
    Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
    Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens.
    Malekzadeh P; Yossef R; Cafri G; Paria BC; Lowery FJ; Jafferji M; Good ML; Sachs A; Copeland AR; Kim SP; Kivitz S; Parkhurst MR; Robbins PF; Ray S; Xi L; Raffeld M; Yu Z; Restifo NP; Somerville RPT; Rosenberg SA; Deniger DC
    Clin Cancer Res; 2020 Mar; 26(6):1267-1276. PubMed ID: 31996390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient induction of cytotoxic T lymphocytes in hepatocellular carcinoma using the HLA-A2-restricted survivin peptide in vitro.
    Zhang S; Zeng C; Wang D; Gao X; Guo S; Zhang Y; Shi L
    Exp Cell Res; 2020 Jan; 386(2):111741. PubMed ID: 31759968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
    Li B; Wang Y; Chen J; Wu H; Chen W
    Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell Responses to
    Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
    Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
    [No Abstract]   [Full Text] [Related]  

  • 14. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
    Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
    Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
    Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
    Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer.
    Yu H; Ye C; Li J; Pan C; Lin W; Chen H; Zhou Z; Ye Y
    Exp Cell Res; 2020 May; 390(1):111953. PubMed ID: 32156601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.
    Lee HJ; Hong CY; Jin CJ; Kim MH; Lee YK; Nguyen-Pham TN; Lee H; Park BC; Chung IJ; Kim HJ; Lee JJ
    Cell Mol Immunol; 2012 Mar; 9(2):175-83. PubMed ID: 22231555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
    Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
    Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database.
    Wu W; Chen Y; Huang L; Li W; Tao C; Shen H
    Oncol Lett; 2020 Nov; 20(5):123. PubMed ID: 32934692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.